The overexpression and amplification of HER-2/ERBB2 are notably more prevalent in serous endometrial carcinomas (ECs) compared to endometrioid endometrial carcinomas (EECs). This evidence concerns the gene ERBB2 and endometrial endometrioid carcinoma.